Prescription required. May be split. Product of Canada. Shipped from Canada.
Generic equivalents for Uloric... What are generics?
Prescription required. Can not be split. Product of UK/EU. Shipped from United Kingdom of Great Britain and Northern Ireland.
To comply with Canadian International Pharmacy Association regulations you are permitted to order a 3-month supply or the closest package size available based on your personal prescription. read more
(feb ux' oh stat)[Posted 11/15/2017] AUDIENCE: Rheumatology, Internal Medicine, Patient ISSUE: FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called allopurinol. FDA required the febuxostat drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when the medicine was approved in 2009. Once the final results from the manufacturer are received, FDA will conduct a comprehensive review and will update the public with any new information. The febuxostat drug labels already carry a Warning and Precaution about cardiovascular events because the clinical trials conducted before approval showed a higher rate of heart-related problems in patients treated with febuxostat compared to allopurinol. These problems included heart attacks, strokes, and heart-related deaths. As a result, FDA required an additional safety clinical trial after the drug was approved and on the market to better understand these differences, and that trial was finished recently. The safety trial was conducted in over 6,000 patients with gout treated with either febuxostat or allopurinol. The primary outcome was a combination of heart-related death, non-deadly heart attack, non-deadly stroke, and a condition of inadequate blood supply to the heart requiring urgent surgery. The preliminary results show that overall, febuxostat did not increase the risk of these combined events compared to allopurinol. However, when the outcomes were evaluated separately, febuxostat showed an increased risk of heart-related deaths and death from all causes. BACKGROUND: Febuxostat is FDA-approved to treat a type of arthritis called gout in adults. Gout happens when a naturally occurring substance in the body called uric acid builds up and causes sudden attacks of redness, swelling, and pain in one or more joints. Febuxostat works by lowering uric acid levels in the blood. RECOMMENDATION: Health care professionals should consider this safety information when deciding whether to prescribe or continue patients on febuxostat. Patients should talk to your health care professionals if you have any questions or concerns. Do not stop taking your medicine without first consulting with your health care professional.
Before taking febuxostat,
- tell your doctor and pharmacist if you are allergic to febuxostat, any other medications, or any of the ingredients in febuxostat. Ask your pharmacist for a list of the ingredients.
- tell your doctor if you are taking azathioprine (Azasan, Imuran), mercaptopurine (Purinethol), or theophylline (Elixophyllin, Theo-24, Uniphyl, others). Your doctor will probably tell you not to take febuxostat if you are taking one or more of these medications.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention cancer chemotherapy medications. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had chest pain; an organ transplant; cancer; a stroke; Lesch-Nyhan syndrome (an inherited disease that causes high levels of uric acid in the blood, joint pain, and problems with motion and behavior); or heart, kidney, or liver disease.
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking febuxostat, call your doctor.
- joint pain
- chest pain
- shortness of breath
- slow or difficult speech
- dizziness or faintness
- weakness or numbness of an arm or leg